Profile data is unavailable for this security.
About the company
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.
- Revenue in USD (TTM)421.00k
- Net income in USD-36.02m
- Incorporated2020
- Employees82.00
- LocationClene Inc.6550 South Millrock Drive, Suite G50SALT LAKE CITY 84121United StatesUSA
- Phone+1 (801) 676-9695
- Fax+1 (302) 531-3150
- Websitehttps://clene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hookipa Pharma Inc | 50.00m | -43.37m | 27.73m | 151.00 | -- | 0.3861 | -- | 0.5545 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Longeveron Inc | 1.85m | -27.37m | 27.74m | 23.00 | -- | 1.08 | -- | 14.98 | -6.67 | -6.67 | 0.2962 | 1.73 | 0.0892 | -- | 7.78 | 80,521.74 | -86.28 | -63.15 | -102.27 | -75.68 | 73.06 | 33.70 | -967.49 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| SAB Biotherapeutics Inc | 1.51m | -45.57m | 28.33m | 57.00 | -- | 0.7678 | -- | 18.73 | -5.84 | -5.84 | 0.1753 | 4.00 | 0.0368 | -- | 31.17 | 26,539.12 | -110.96 | -- | -142.16 | -- | -- | -- | -3,012.26 | -- | -- | -- | 0.0856 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 29.03m | 8.00 | -- | 4.11 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -14.40m | 29.61m | 20.00 | -- | 1.85 | -- | -- | -0.9868 | -0.9868 | 0.00 | 0.8654 | 0.00 | -- | -- | 0.00 | -64.98 | -- | -83.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Hcw Biologics Inc | 3.50m | -37.33m | 29.79m | 45.00 | -- | -- | -- | 8.52 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | 1.16m | 30.12m | 1.00 | 25.98 | 0.9633 | 13.58 | -- | -0.2094 | -0.2094 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | 2.39 | -- | 3.04 | -- | -- | -- | -- | -- | -- | -- | 0.189 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Surrozen Inc | 10.00m | -44.44m | 30.22m | 42.00 | -- | 5.33 | -- | 3.02 | -17.05 | -17.05 | 3.81 | 1.74 | 0.1961 | -- | 1.41 | 238,095.20 | -87.16 | -- | -99.66 | -- | -- | -- | -444.38 | -- | -- | -1.43 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Clene Inc. | 421.00k | -36.02m | 30.40m | 82.00 | -- | -- | -- | 72.22 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 31.81m | 21.00 | -- | 1.20 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 31.89m | 22.00 | -- | 0.3482 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.21m | -- | -- | 43.15 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 32.75m | 32.00 | -- | 0.5835 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Passage Bio Inc | 0.00 | -68.80m | 33.11m | 58.00 | -- | 0.4553 | -- | -- | -1.17 | -1.17 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -48.97 | -48.56 | -56.34 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
Data as of Nov 22 2024. Currency figures normalised to Clene Inc.'s reporting currency: US Dollar USD
12.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 682.37k | 8.57% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 131.11k | 1.65% |
| Scoggin Management LPas of 30 Sep 2024 | 75.00k | 0.94% |
| Geode Capital Management LLCas of 30 Sep 2024 | 42.57k | 0.54% |
| Lunt Capital Management, Inc.as of 30 Sep 2024 | 29.54k | 0.37% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 15.91k | 0.20% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 15.00k | 0.19% |
| Castleview Partners LLCas of 30 Sep 2024 | 12.78k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 11.50k | 0.14% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.17k | 0.05% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
